Mitotane currently represents the treatment of choice for adrenocortical carcinoma. Clinical evidence shows the appearance of hypogonadism following treatment with this drug, observed more frequently in male patients. Previously we have demonstrated the effect of this drug on the ovary in mouse. The aim of this study, therefore, will be to evaluate the impact of mitotane treatment on male gonadal function. The experimentation will be conducted on CD1 mice subjected to mitotane treatment. In male gonads, we intend to study the histological and functional effect induced by the drug. Morphology, cell proliferation and differentiation by immunofluorescence, immunohistochemistry and PCR-Multiplex will be assessed in the cells from the gonads of the treated animals. In addition will be evaluated the effect of mitotane treatment on sperm count and DNA fragmentation.
